Johnson & Johnson announced that the FDA Oncologic Drugs Advisory Committee (ODAC) recommends Carvykti (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed or refractory multiple… read more.
Pfizer Inc. announced the FDA has granted accelerated approval to Elrexfio (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
